SecBot SecBot

ALLR

Allarity Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001860657 Biotech & Drug Discovery
$0.9150 +0.05 (+5.78%)
Oct 26 4:00 PM ET · prev $0.8650
Market cap
$13.5M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$11.00
+1102% · range $11.00–11.00
Next earnings
Nov 14
in 18 days · EPS est. −$0.21
1 year
−31.7%
from $1.34 · Oct 27
30 days
−5.5%
from $0.9680
52-week range
$0.8100–1.77
−48% from high · low Feb 5
Avg volume 20D
124.1K
Oct 12 spike 415.2K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 3/7 ·Next Earnings date, Nov 14, 2026
Strongest BULLISH Allarity Therapeutics announced the Japan Patent Office granted patent No. 7917283 covering its…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.250 → −$0.210 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD331,509$427.6K
NORTHERN TRUST CORPADD48,103$52.4K
RENAISSANCE TECHNOLOGIES LLCDOUBLED247,612$267.4K
Private Advisor Group, LLCNEAR_EXIT55,536$60.0K
NORTHERN TRUST CORPTRIM28,942$31.3K
TWO SIGMA INVESTMENTS, LPADD27,492$29.7K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED151,927$240.0K
GEODE CAPITAL MANAGEMENT, LLCADD50,650$51.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1102%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 16, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 8, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 30, 2026
Graff Jeremy R.
See Remarks
EXERCISE39,494 sh
Sep 30, 2026
Graff Jeremy R.
See Remarks
TAX W/H$14.2K
Jan 28, 2026
Jensen Thomas
CEO
AWARD200,000 sh
Jan 28, 2026
McLaughlin Gerald W.
Director
AWARD45,000 sh
Jan 28, 2026
Ervin Jeffrey S
CFO
AWARD150,000 sh
Jan 28, 2026
Graff Jeremy R.
See Remarks
AWARD133,333 sh
Jan 22, 2026
Graff Jeremy R.
See Remarks
EXERCISE48,147 sh
Jan 22, 2026
Graff Jeremy R.
See Remarks
TAX W/H$21.0K

Earnings setup

Estimates
Nov 14
reports in 18 days
−$0.21
EPS estimate, this quarter
+16%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.21–-$0.21+16.0%$0.00
Next Q-$0.21-$0.21–-$0.21+16.0%$0.00
Current FY-$0.80-$0.80–-$0.80+13.0%$25.0K
Next FY-$0.86-$0.86–-$0.86+11.3%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 SEC
Allarity Therapeutics issued a press release highlighting recent advances in its Drug Response Predictor (DRP)…
8-K — Impact 3/10
Sep 30, 2026 Insider
Graff Jeremy R. acquired via exercise 39,494 shares
See Remarks
Sep 30, 2026 Insider
Graff Jeremy R. surrendered for taxes 14,613 shares
See Remarks @ $0.9700 ($14.2K)
Sep 29, 2026 SEC
Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line…
8-K — Impact 2/10
Sep 28, 2026 Press
Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line…
Impact 3/10
Sep 28, 2026 Announcement
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New
Sep 16, 2026 SEC
Allarity Therapeutics announced the Japan Patent Office granted patent No. 7917283 covering its stenoparib-specific…
8-K — Impact 5/10
Sep 11, 2026 Press
Allarity Therapeutics announced that its newly formed SPAC subsidiary, Allarity Acquisition Corp., filed an S-1…
Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 14, 2026
Earnings date
ALLR Q3 2026 Earnings Scheduled — 2026-11-14
Recent
Sep 28, 2026
Announcement
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will…
Sep 11, 2026
Announcement
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Aug 15, 2026
Earnings date
ALLR Q2 2026 Earnings Scheduled — 2026-08-15
Aug 14, 2026
Announcement
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash
Jun 18, 2026
Announcement
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

SecBot reports

12 filings · 8 press releases · 4 bullish · 0 bearish · 8 neutral
All ALLR filing & press-release reports (20)